This article explores the transformative shift occurring in the treatment of lung cancer through personalized approaches, driven by a deep understanding of the genomic landscape. Genomic profiling, facilitated by advanced sequencing technologies, enables the decoding of intricate genetic alterations within lung tumors. Identification of targetable mutations, such as EGFR, ALK, and ROS1, provides the basis for precision therapies that have significantly improved patient outcomes. The integration of immunotherapy, specifically PD-1/PD-L1 inhibitors, into personalized treatment plans, along with the exploration of combination strategies, further enhances the anti-cancer response. Liquid biopsies, analyzing circulating tumor DNA, offer real-time monitoring and early detection of resistance, contributing to the ongoing adaptability of treatment plans. Challenges such as tumor heterogeneity and the identification of resistance mechanisms are acknowledged, emphasizing the need for continued research and innovative strategies. As personalized medicine evolves, it holds the promise to transform lung cancer treatment, offering a more precise and effective approach tailored to the unique genomic features of each patient's tumor.
HTML PDFShare this article
Journal of Cancer Clinical Trials received 95 citations as per Google Scholar report
